Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	1	of	8	**Attorney Docket No.**	**373987-011US (102895)**

U.S. PUBLISHED DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Publication Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code *(if known)*		

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation[2]	
		Office	Number	Kind Code *(if known)*			Yes	No

OTHER DOCUMENTS - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation[2]	
			Yes	No
	C29	ANDRINGA, G. *et al.*, "TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates," *Neurobiol. Dis.* 14:205-217 (2003) (Exhibit 72)		
	C30	BENEDETTI, M. S. *et al.*, 1994, "The Anticonvulsant FCE 26743 is a Delective and Short-Acting MAO-B Inhibitor Devoid of Inducing Properties Towards Cytochrone P450-dependent Testosterone Hydroxylation in Mice and Rats," *J. Pharm. Pharmacol.* 46:814-819 (Exhibit 74)		
	C31	CALNE, D. B. *et al.*, "Manganism and Idiopathic Parkinsonism, Similarities and Differences," *Neurology* 44:1583-1586 (1994) (Exhibit 66)		
	C32	CHAUDHURI, K. R. *et al.*, "International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study," *Movement Disorders* 21:916-923 (2006) (Exhibit 47)		
	C33	CHAUDURI, K. R. *et al.*, "The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study," *Movement Disorders* 22:1901-1911 (2007) (Exhibit 45)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	2	of	8	**Attorney Docket No.**	**373987-011US (102895)**

	C34	CHO, C. *et al.*, "A model-based approach for assessing Parkinsonian gait and effects of levodopa and deep-brain stimulation," *IEEE Engineering in Medicine and Biology Society Conference Proceedings,* 1228-1231 (2006) (Exhibit 48)		
	C35	*CURRICULUM VITAE* of C. Warren Olanow, M.D., FRCPC (Exhibit 69)		
	C36	DUBOIS, B. *et al.*, "Diagnostic Procedures for Parkinson's disease dementia: Recommendations from the Movement Disorder Society Task Force," *Movement Disorders* 22:2314-2324 (2007) (Exhibit 44)		
	C37	EMRE, M. *et al.*, "Clinical diagnostic criteria for dementia associated with Parkinson's disease," *Movement Disorders* 22:1689-1707 (2007) (Exhibit 43)		
	C38	FAHN, S., Parkinson Study Group, "Levodopa and the progression of Parkinson disease," *N. Eng. J. Med.* 351: 2498-2508 (2004) (Exhibit 2)		
	C39	FREEMAN, T. B. *et al.*, "Use of placebo surgery in a controlled trial of a cellular-based therapy for Parkinson's disease," *N. Engl. J. Med.* 341:988-992 (1999) (Exhibit 32)		
	C40	FREEMAN, T. B. *et al.*, "Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's Disease," *Ann. Neurol.* 38:379-388 (1995) (Exhibit 39)		
	C41	GERMANO, I. M. *et al.*, "Unilateral stimulation of the subthalamic nucleus in Parkinson's disease: a double blind 12-month study," *J. Neurosurgery* 101:36-42 (2004) (Exhibit 26)		
	C42	GOETZ,, C. G. *et al.*, "Movement disorder society-sponsored revision of the Unified Parkinson Disease Rating Scale (MDS-UPDRS): Process, format and clinimetric testing plan," *Movement Disorders* 22:41-47 (2007) (Exhibit 46)		
	C43	GOETZ, C. G. *et al.*, "Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial," *Movement Disorders* 22:179-186 (2007) (Exhibit 18)		
	C44	GOETZ, C. G. *et al.*, "Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results," *Movement Disorders* 23:2129-2170 (2008) (Exhibit 41)		
	C45	GOOD, P. F. *et al.*, "Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: A LAMMA study," *Brain Res.* 593:343-346 (1992) (Exhibit 62)		
	C46	HUANG, C. *et al.*, "Progression after chronic manganese exposure," *Neurology* 43:1479-1483 (1993) (Exhibit 64)		
	C47	HAUSER, R. A. *et al.*, "Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease," *Arch. Neurol.* 56(2):179-87 (1999) (Exhibit 31)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	3	of	8	**Attorney Docket No.**	**373987-011US (102895)**

	C48	HAUSER, R. A. *et al.*, "Blood manganese correlates with brain magnetic resonance imaging changes in patients with liver disease," *Can. J. Neurol. Sci.* 23:95-98 (1996) (Exhibit 59)		
	C49	JENNER, P. *et al.*, "Oxidative stress and the pathogenesis of Parkinson's disease," *Neurology* 47 (suppl 3):161-170 (1996) (Exhibit 58)		
	C50	KOLLER, W. *et al.*, "High frequency unilateral thalamic stimulation in the treatment of essential and Parkinsonian tremor," *Ann. Neurol.* 42:292-299 (1997) (Exhibit 24)		
	C51	KORDOWER, J. H. *et al.*, "Dopaminergic transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery," *Exp. Neurology* 144:41-46 (1997) (Exhibit 35)		
	C52	KORDOWER, J. H. *et al.*, "Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants," *Cell. Transp.* 6: 213-219 (1997) (Exhibit 34)		
	C53	KORDOWER, J. H. *et al.*, "Neuropathologic evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease," *N. Engl. J. Med.* 332:1118-1124 (1995) (Exhibit 38)		
	C54	KORDOWER, J. H. *et al.*, "Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, quantitative, ultrastructural, and metabolic studies," *J. Comparative Neurol.* 370:203-230 (1996) (Exhibit 37)		
	C55	KORDOWER, J. H. *et al.*, "Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease," *Movement Disorders* 13(3):383-93 (1998) (Exhibit 33)		
	C56	KORDOWER, J. H. *et al.*, "Transplanted dopaminergic neurons develop PD pathologic changes: a second case report," *Movement Disorders* 23:2303-2306 (2008) (Exhibit 28)		
	C57	KORDOWER, J. H. *et al.*, "Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease," *Nature Med.* 14:504-506 (2008) (Exhibit 29)		
	C58	LIEBERMAN, A. *et al.*, "A multi-center trial of ropinirole as adjunct treatment for Parkinson's disease," *Neurology* 51:1057-1062 (1998) (Exhibit 8)		
	C59	MARKS, W. J. *et al.*, "Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial," *Lancet Neurol.* 7:400-408 (2008) (Exhibit 40)		
	C60	MARTINEZ-MARTIN, P. *et al.*, "Prevalence of nonmotor symptoms in Parkinson's disease in an international setting: study using nonmotor symptoms questionnaire in 545 patients," *Movement Disorders* 22:1623-1629 (2007) (Exhibit 42)		
	C61	MCNAUGHT, K. *et al.*, "Proteasomal dysfunction in sporadic Parkinson's disease," *Neurology* 66(10 Suppl 4):S37-49 (2006) (Exhibit 49)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	4	of	8	**Attorney Docket No.**	**373987-011US (102895)**

	C62	MCNAUGHT, K. *et al.*, "Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures," *J. Neurochem* 81: 301-306 (2002) (Exhibit 52)		
	C63	MCNAUGHT, K. *et al.*, "Proteasomal inhibition causes nigral degeneration with inclusion bodies in rats," *NeuroReport* 13:1437-1441 (2002) (Exhibit 53)		
	C64	MCNAUGHT, K. *et al.*, "Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease," *Ann. Neurol.* 56:149-162 (2004) (Exhibit 56)		
	C65	MCNAUGHT, K. *et al.*, "Failure of the ubiquitin-proteasome system in Parkinson's disease," *Nature Reviews Neuroscience* 2: 589-594 (2001) (Exhibit 54)		
	C66	MCNAUGHT, K. *et al.*, "Proteasome inhibitior- induced model of Parkinson's disease," *Ann. Neurol.* 60:243-247 (2006) (Exhibit 55)		
	C67	MORRISON, C. E. *et al.*, "A program for neuropsychological investigation of deep brain stimulation (PNIDBS) in movement disorder patients: development, feasibility, and preliminary data," *Neuropsychiatry, Neuropsychol. Behav. Neurol.* 13:204-219 (Exhibit 23)		
	C68	MYTILINEOU, C. *et al.*, "L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro," *J. Neurochem.* 68:434-436 (1997) (Exhibit 76)		
	C69	MYTILINEOU, C. *et al.*, "Inhibition of Proteasome Activity Sensitizes Dopamine Neurons to Protein Alterations and Oxidative Stress," *J. Neural Transmission* 111:1237-1251 (2004) (Exhibit 51)		
	C70	NAIR, V. D. *et al.*, "P53 mediates non-transcriptional cell death in dopaminergic cells in response to proteasome inhibitors," *J. Biol. Chem.* 281:39550-39560 (2006) (Exhibit 50)		
	C71	OLANOW, C. W. *et al.*, "Free Radicals and Neurodegeneration," *Trends Neurosci.* 17: 193-194 (1994) (Exhibit 65)		
	C72	OLANOW, C. W. *et al.*, "A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease," *Ann Neurol.* 54(3):403-14 (2003) (Exhibit 30)		
	C73	OLANOW, C. W. *et al.*, "The role of deep brain stimulation as a surgical treatment for Parkinson's disease," *Neurology* 55 (suppl. 6):60-66 (2000) (Exhibit 25)		
	C74	OLANOW, C. W. *et al.*, "Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in Parkinson's disease: a double-blind video-based analysis," *Movement Disorders* 24:336-343 (2009) (Exhibit 27)		
	C75	OLANOW, C. W. *et al.*, "Fetal nigral transplantation as a therapy for Parkinson's disease," *Trends. Neurosci.* 19:102-109 (1996) (Exhibit 36)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	5	of	8	**Attorney Docket No.**	**373987-011US (102895)**

	C76	OLANOW, C. W. *et al.*, "An open multi-center trial of Sinemet CR in levodopa naïve Parkinson's disease patients," *Clin. Neuropharm.* 14:235-240 (1991) (Exhibit 3)		
	C77	OLANOW, C. W. *et al.*, "Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease," *Adv. in Neurol.* 45:555-560 (1987) (Exhibit 4)		
	C78	OLANOW, C. W. *et al.*, "Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease," *Clinical Neuropharm.* 10:178-185 (1987) (Exhibit 5)		
	C79	OLANOW, C. W. *et al.*, "A multi-center, double-blind, placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease," *Movement Disorders* 9: 40-47 (1994) (Exhibit 77)		
	C80	OLANOW, C. W. *et al.*, "The effect of deprenyl and levodopa on the progression of Parkinson's disease," *Ann. Neurol* 38: 771-777 (1995) (Exhibit 78)		
	C81	OLANOW, C. W., (for the Tasmar advisory board), "Tolcapone and hepatotoxic effects," *Arch. Neurol.* 57:263-267 (2000) (Exhibit 9)		
	C82	OLANOW, C. W. *et al.*, "Tolcapone: An Efficacy and Safety Review (2007)," *J. Clin. Neuropharm* 30:287-294 (2007) (Exhibit 10)		
	C83	OLANOW, C. W. *et al.*, "Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson's disease," *Arch. Neurol.* 61:1563-1568 (2004) (Exhibit 11)		
	C84	OLANOW, C. W. *et al.*, "A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics," *Movement Disorders* 23:2194-2201 (2008) (Exhibit 13)		
	C85	PARKINSONS STUDY GROUP, Olanow, C.W., Steering Committee, "Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease," *N. Eng. J. Med.* 328:176-183 (1993) (Exhibit 75)		
	C86	OLANOW, C. W., "An Introduction to the Free Radical Hypothesis in Parkinson's Disease," *Ann. Neurol.* 32:2-9 (1992) (Exhibit 61)		
	C87	OLANOW, C. W. *et al.*, "CV205-502: Safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind placebo crossover study," *Clinical Neuropharm.* 12:490-497 (1989) (Exhibit 15)		
	C88	OLANOW, C. W. *et al.*, "TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial," *Lancet Neurol.* 5:1013-1020 (2006) (Exhibits 16 and 73)		
	C89	OLANOW, C. W. *et al.*, "Multicenter, open-label, trial of Sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID study)," *Clin. Neuropharm.* 27:58-62 (2004) (Exhibit 17)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	6	of	8	**Attorney Docket No.**	**373987-011US (102895)**

	C90	OESTREICHER, E. *et al.*, "Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study," *Brain Res.* 660: 8-18 (1994) (Exhibit 60)		
	C91	PARKINSON STUDY GROUP (C.W. Olanow, Steering Committee), "Safety and efficacy of pramipexole in early Parkinson's disease: a randomized dose-ranging study," *JAMA* 278:125-130 (1997) (Exhibit 7)		
	C92	PARKINSON STUDY GROUP (C.W. Olanow, Steering Committee), "Effect of Deprenyl on the progression of disability in early Parkinson's disease," *N. Engl. J. Med.* 321:1364-1371 (1989) (Exhibit 6)		
	C93	PARKINSON STUDY GROUP (Olanow CW, Steering Committee), "A controlled clinical trial of lazabemide (Ro 19-6327) in untreated Parkinson's disease," *Ann. Neurol.* 33:350-356 (1993) (Exhibit 19)		
	C94	PARKINSON STUDY GROUP (Olanow CW, Steering Committee), "A controlled trial of lazabemide (Ro 19-6327) in levodopa treated Parkinson's disease," *Arch. Neurol.* 51:342-347 (1994) (Exhibit 20)		
	C95	PARKINSON STUDY GROUP (Olanow CW, Steering Committee), "Effect of lazabemide on the progression of disability in early Parkinson's disease," *Ann. Neurol.* 40:99-107 (Exhibit 21)		
	C96	SCHWARTZ, A. M. *et al.*, "Double-blind controlled study of MK-486," *Transactions of the Amer. Neurol. Ass'n* 98:301-303 (1973) (Exhibit 1)		
	C97	SENGSTOCK, G. J. *et al.*, "Infusion of iron into the rat substantia nigra: nigral pathology and dose-dependent loss of striatal dopaminergic markers," *J. Neurosci. Res.* 35:67-82 (1993) (Exhibit 63)		
	C98	SENGSTOCK, G. J. *et al.*, "Intranigral iron infusion in the rat. Acute elevations in nigral lipid peroxidation and striatal dopaminergic markers with ensuing nigral degeneration," *Biol. Trace Elem. Res.* 58:177-195 (1997) (Exhibit 57)		
	C99	SENGSTOCK, G. J. *et al.*, "Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra," *Exp. Neurol.* 130:82-94 (1994) (Exhibit 68)		
	C100	SHINOTOH, H. *et al.*, "MRI and PET studies of manganese-intoxicated monkeys," *Neurology* 45:1199-1204 (1995) (Exhibit 67)		
	C101	SMITH, L. A. *et al.*, "Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates," *Movement Disorders* 20:306-314 (2005) (Exhibit 71)		
	C102	STERN, M. B. *et al.*, "A double-blind, randomized controlled trial of rasagiline as monotherapy in early Parkinson's disease patients," *Movement Disorders* 19:916-923 (2004) (Exhibit 12)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./

Substitute for form 1449A/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				**Application Number**	**10/559,982**
				Filing Date	**February 2, 2006**
				First Named Inventor	**Ruggero Fariello**
				Group Art Unit	**1617**
(Use as many sheets as necessary)				**Examiner Name**	**Sahar JAVANMARD**
				Confirmation No.	**6583**
Sheet	7	of	8	**Attorney Docket No.**	**373987-011US (102895)**

	C103	STOCCHI, F. *et al.*, "Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's Disease," *Brain* 125:2058-2066 (2002) (Exhibit 14)		
	C104	THE DEEP BRAIN STIMULATION FOR PD STUDY GROUP (Obeso and Olanow, corresponding authors), "Deep brain stimulation of the subthalamic nucleus of the globus pallidus pars interna in Parkinson's disease," *New Engl. J. Med.* 345:956-963 (2001) (Exhibit 22)		
	C105	Maj, R. *et al.*, 1999, "PNU-141774E, A Combined MAO-B and Glutamate Release Inhibitor, is Effective in Animal Models of Parkinson's Disease," Society for Neuroscience, Vol. 25, p. 1599 (Exhibit 70)		

Examiner Signature	/Sahar Javanmard/	Date Considered	09/13/2009

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation or translation of abstract is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.J./